IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0195945.html
   My bibliography  Save this article

Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab

Author

Listed:
  • Coraline Dumenil
  • Marie-Ange Massiani
  • Jennifer Dumoulin
  • Violaine Giraud
  • Sylvie Labrune
  • Thierry Chinet
  • Etienne Giroux Leprieur

Abstract

Introduction: The prognosis of advanced non-small-cell lung cancer (NSCLC) has been improved by development of immune checkpoint inhibitors (ICIs) such as nivolumab for second-line treatment. As phase III trials include only selected patients, we here investigated the clinical factors associated with efficacy and safety of nivolumab in ‘real life’ patients with advanced NSCLC. Methods: Clinical and histological characteristics, therapies and survival data of all consecutive patients with advanced NSCLC included prospectively and treated by nivolumab in two French academic hospitals between February 2015 and December 2016 were examined. Results: Sixty-seven patients were included, mostly male (69%), current or former smokers (87%) with PS

Suggested Citation

  • Coraline Dumenil & Marie-Ange Massiani & Jennifer Dumoulin & Violaine Giraud & Sylvie Labrune & Thierry Chinet & Etienne Giroux Leprieur, 2018. "Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab," PLOS ONE, Public Library of Science, vol. 13(4), pages 1-15, April.
    • Handle: RePEc:plo:pone00:0195945
    DOI: 10.1371/journal.pone.0195945
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0195945
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0195945&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0195945?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0195945. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.